A Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo in Patients With Acute Allergic Conjunctivitis

Study Identifier
GMA-LAS-12-023
CT.gov Identifier
NCT01732757
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Study Details

Medical Condition
  • Conjunctivitis
    • Study Drug
  • Alcaftadine 0.25%
  • Olopatadine 0.2%
  • dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%
    • Phase
    Phase 4
    Sex
    Female & Male
    Age
    10+ years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * History of ocular allergies within the past 24 months. * Able to avoid wearing contact lenses for at least 72 hours prior to and during the study trial period.
    Exclusion Criteria:
    * Any presence of active ocular infection or history of an ocular herpetic infection. * Ocular surgery within 3 months prior to the first visit or refractive surgery within the past 6 months. * Have any planned surgery during the study or 30 days after the study.

    Protocol Summary

    This study will evaluate the efficacy of Lastacaft® (Alcaftadine 0.25%) and Pataday™ (Olopatadine 0.2%) as compared to each other and to placebo in the prevention of ocular itching associated with allergic conjunctivitis.

    Study Locations

    Location
    Status
    Location
    Memphis, Tennessee, United States
    Status
    Not applicable